



WELLFULLY



INVESTOR CALL
APRIL 29, 2022

This presentation contains certain “forward-looking statements” concerning Wellfully. Where Wellfully expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with Wellfully and the industry which may affect the accuracy of the forward-looking statements. Wellfully does not undertake any obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

WELLFULLY INVESTMENT HIGHLIGHTS



A HIGHLY INNOVATIVE WELLNESS COMPANY WITH GLOBALLY DISRUPTIVE PRODUCTS

About Wellfully Limited (ASX:WFL)

Wellfully Limited ('Wellfully' or 'the Company') is the world's first fully-integrated, science-based wellness company. Over the past two years, the Company has leveraged its vast enhanced drug deliveries technology inventory and developed industrial infrastructure and its own product portfolio.

Wellfully is active in the highly attractive beauty and personal care, beauty device, as well as the health and pain relief markets delivering innovative products through collaborations with industry majors spanning licensing, joint development and OEM, as well as with its own global cosmetic and healthcare brands, RÉDUIT and SWISSWELL, positioned to disrupt these global blockbuster markets.


Supported by a highly experienced Board and Management, Wellfully is poised to deliver notable and sustainable results.

Corporate Snapshot*

Share Price	\$0.077
Shares on Issue	~249.8m
Options on Issue	~201m
Market Capitalisation (fully diluted)	~\$20.73m
Cash (as at 31 Dec 2022)	~\$3.1m
Net Debt	Nil
Top 20	40.01%
Board & Management	9.29%

*Share price, market capitalisation, share holdings as at 28 April

Share Price Performance



QUARTERLY CASH FLOW REPORT

- Receipts
- Outflows


LOOKING AHEAD

- Key milestones
- Financing strategy

POSITIVE PERFORMANCE ACROSS ALL FRONTS

CASH RECEIPTS

in AUD 000s



KEY COMMENTS


- R&D income and technology licensing increased from \$40k in Q2 2022 to \$122k (+205%)
- Own brands receipts increased from \$160k in Q2 2022 to \$205k (+80%)
- Without government subsidies the receipts increased from \$200k in Q2 2022 to \$410k (105%)
- With government subsidies the cash receipts increased from \$200k in Q2 2022 to \$825k (+312%)

Good performance in cash receipts across all business streams, despite the halt of the important Bork collaboration due to the crisis in Ukraine, stands testament to the solid foundation of the Company.

POSITIVE PERFORMANCE ACROSS ALL FRONTS

CASH OUTFLOWS AND NET OPERATIONS CASH

in AUD 000s



KEY COMMENTS

- Compared to Q2 2022, all cash outflows were reduced except for the advertising & marketing (+8% due to Kickstarter RÉDUIT Boost campaign) for a total of \$-488k from \$3.130k of outflows in Q2 2022, to \$2.642k (-16%);
- Combined with the increase in receipts, the net burn in cash from operations was reduced by \$-1.113k (-38%) from \$2.930k in Q2 2022 to \$1.817k in Q3 2022.

The effect of the increase in cash receipts was additionally aided by a reduction of cash outflows for a significant improvement in overall operations cash from as compared to Q2 2022 of 38%.

QUARTERLY CASH FLOW REPORT

- Receipts
- Outflows

LOOKING AHEAD

- Key milestones
- Financing strategy

DEVELOPMENT STRATEGY

OPERATIONAL TARGETS

KEY MILESTONES

RÉDUIT

- Commercial presence across 2.300 preferred points-of-sale with selected premium beauty retailers;
- Range completion across devices, pods and enhanced delivery patches;


SWISSWELL

- Process and supply-chain insourcing of patches for better product availability and cost;
- Range extension across other joint and tissue pain applications;
- Securing commercial presence across 14.300 preferred points-of-sale in health and wellness retail outlets;

Collaborations

- Development of existing and acquisition of new collaborations scaling product and industrial platforms;

EXAMPLE SENSITIVITY



* Market share and equivalent value as per the investor call presentation from April 14, 2022;

SHORT-TERM FINANCING STRATEGY

SUPPORTING THE DEVELOPMENT

WELLFULLY

FINANCING USED IN THE PAST

- Public placements
- Rights issues

CONSTRAINTS

Limited scale
Short-term positions
Limited access

POTENTIAL FINANCING UNDER CONSIDERATION

- Equity funding facilities
- Private placements
- Share purchase plans

BENEFITS

Larger scale
Long-term positions
Wide access

The aim is to secure different funding mechanisms to be used together in answering to the Company's operations financing requirements, each at the right time and scale, but also each with a particular role in terms of relevant considerations of existing and new investors.

WELLFULLY

COMPANY

Email: henko.vos@nexiaperth.com.au

ADVISORS

Matthew Wright – NRW Communications

Email: matt@nwrcommunications.com.au

Phone: +61 451 896 420

ADDRESS

Wellfully Ltd - 284 Oxford Street, WA, 6007, Leederville Australia



Thank
You